• HOME
  • R&D
  • Vactosertib

환자를 위한
치료법 개발

Vactosertib

백토서팁 작용기전

백토서팁은 기존의 모든 암치료제와 병용 가능

TGF-β1은 암조직 주변의 기질세포에 작용하여 기질을 대량으로 생산해 암을 둘러싼 벽을 생성

- 항암제나 면역세포가 암조직에 침투하지 못하게 하는 역할

TGF-β1 신호전달 억제제인 백토서팁은 암 조직 주변의 기질 벽의 생성을 억제

- 다양한 암 치료제가 암세포를 공격할 수 있도록 도움을 줌

Without 백토서팁
항암제 단일투여

면역 세포 침투 불능, 항암제 비반응,
항암제 내성 발생

With 백토서팁
항암제 병용투여

암의 성장억제

다양한 임상 진행

백토서팁의 가치를 높이기 위해
다양한 암종의 치료 가능성을 증명하는 다수의 임상 진행

임상시험 개발 진행현황
구분 단독/병용 암종 임상시험 개발 진행현황 사이트 스폰서
단독 백토서팁 단독 골육종 임상 1/2상 진행중 미국 한국 매드팩토
골수증식종양 임상 2상 종료 미국 Weill Medical College of Cornell University
진행형 고형암 임상 1상 종료 한국 매드팩토
진행형 고형암 임상 1/2상 종료 미국 매드팩토
골수형성이상증후군 임상 1상 종료 미국 매드팩토
면역항암제 키트루다(펨브롤리주맙) 병용MSD 대장암 임상 2B/3상 진행중 미국 한국 매드팩토
대장암, 위암 임상 1B/2A상 종료 한국 매드팩토
대장암 임상 2상 진행중 미국 University of California (Chloe Atreya)
비소세포폐암 1L 임상 2상 종료 한국 매드팩토
흑색종 임상 2상 종료 한국 연세대학교
임핀지(더발루맙) 병용AstraZeneca 비소세포폐암 2L 임상 1B/2A상 종료 한국 매드팩토
위암 임상 2상 진행중 한국 국립암센터
화학요법 탁솔(파클리탁셀) 병용 위암 임상 1B/2A상 종료 한국 매드팩토
탁솔(파클리탁셀) + 사이람자(라무시루맙) 병용 위암 임상 2A상 진행중 한국 삼성서울병원
폴폭스(FOLFOX) 병용 췌장암 임상 1B상 종료(예정) 한국 삼성서울병원
오니바이드(nal-IRI/FL) 병용 췌장암 임상 1B상 진행중 한국 삼성서울병원
글리벡(이매티닙) 병용 데스모이드종양 임상 1B/2A상 종료 한국 연세대학교
포말리스트(포말리도마이드) 병용 다발성 골수종 임상 1B상 종료 미국 Case Comprehensive Cancer Center
화학방사선치료 표준 요법 병용 식도암 임상 2상 진행중 미국 Case Comprehensive Cancer Center
NK세포치료제 NK세포치료재 및 인터루킨(IL-2) 병용 대장암, 혈액암 임상 1B상 진행중 미국 Case Comprehensive Cancer Center

‘Clinicaltrial.gov’ Status – SIT for Vactosertib

‘Clinicaltrial.gov’ Status – SIT for Vactosertib
No. Protocol No. Indication Phase Combination NCT No. Study title Actual Status
1 MP-001
(MP-VAC-101)		 Solid cancer 1 NA NCT02160106 First-in-Human Dose-Escalation Study of TEW-7197 Monotherapy in Subjects with Advanced-Stage Solid Tumors Completed
2 MP-GC-01
(MP-VAC-102)		 GC 1b/2a Paclitaxel NCT03698825 An Open-label, Multi center Phase ib/2a study of TEW-7197 (Vactosertib) plus Weekly Paclitaxel as Second-line Treatment for Metastatic Gastric Adenocarcinoma Completed
3 MP-VAC-105 Food effect 1 NA NCT03704675 A randomized, open, cross-over design clinical trial to investigate the safety, tolerability, and pharmacokinetics of TEW-7197 after a single oral administration of TEW-7197 200mg under fed or fasting conditions in healthy male subjects Completed
4 MP-MDS-01 MDS 1/2 NA NCT03074006 Phase1/2 Study of TEW-7197 Monotherapy in Patients with Low or Intermediate Myelodysplastic Syndromes (MDS) Completed
5 MP-VAC-202 Urothelial 2 Durvalumab NCT04064190 A Phase 2 Study of TGF-b inhibitions (Vactosertin) with Anti-PD-L1 (Durvalumab) in Patients with Advanced or Recurrent Urothelial Carcinoma Failing to Achieve Response with Checkpoint Inhibition Withdrawn
6 MP-VAC-203 NSCLC 1b/2a Durvalumab NCT03732274 Phase 1b/2a, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Durvalumab in Patients With Advanced Non Small Cell Lung Cancer Who Progressed Following Platinum-based Chemotherapy Active, not recruiting
7 MP-VAC-204 mCRC 1b/2a Pembrolizumab NCT03724851 A Phase 1b/2a Study to Assess the Safety, Tolerability, PK, and Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Patients With Metastatic Colorectal or Gastric Gastroesophageal Junction Adenocarcinoma Active, not recruiting
8 MP-VAC-205 NSCLC 2 Pembrolizumab NCT04515979 A Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of Vactosertib in Combination With Pembrolizumab as a First-line Treatment for Subjects With PD-L1 Positive Advanced Non-Small Cell Lung Cancer Active, not recruiting
9 MP-VAC-206 Desmoid 2 Imatinib NCT06219733 A Phase II, Open-Label, Randomized, Controlled Study to Evaluate Efficacy and Safety of Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor (Aggressive Fibromatosis) Compared With Imatinib Monotherapy Withdrawn
10 MP-VAC-209 Osteosarcoma 1b/2a NA NCT05588648 A Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib as a Single Agent in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma Recruiting

‘Clinicaltrial.gov’ Status – IIT for Vactosertib

‘Clinicaltrial.gov’ Status – IIT for Vactosertib
No. Protocol No. Indication Phase Combination NCT No. Study title Actual Status
1 IN-VAC-101 Multiple Myeloma 1 Pomalidomide NCT03143985 A Phase 1b Trial of Vactosertib in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM) Completed
2 IN-VAC-103 PDAC 1 Nal-IRI/​FL NCT04258072 Phase 1b Study of Vactosertib (TEW-7197) in Combination With Nal-IRI／FL in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine／Nab-Paclitaxel Recruiting
3 IN-VAC-104 CRC & AML 1 NK Cell + IL-2 NCT05400122 A Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer and Relapsed/Refractory Hematologic Malignancies Recruiting
4 IN-VAC-201 Desmoid 1/2 Imatinib NCT03802084 A Phase 1b/2a, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Imatinib in Patients With Advanced Desmoid Tumor (Aggressive Fibromatosis) Completed
5 IN-VAC-202 MPNs 2 NA NCT04103645 A 2-tiered, Phase 2, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) in the Treatment of Anemic Patients With Philadelphia Chromosome-negative MPNs (Ph-neg MPNs) Terminated
6 IN-VAC-203 Gastric 2 Paclitaxel+
Ramucirumab		 NCT04656002 As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers Recruiting
7 IN-VAC-205 CRC,
resectable Hepatic Metastases		 2 NA NCT03844750 A Phase II Study of Preoperative Immunotherapy in Patients With Colorectal Cancer and Resectable Hepatic Metastases Recruiting
8 IN-VAC-207 Gastric 2 Durvalumab NCT04893252 Vactosertib in Combination With Durvalumab (MEDI4736) in Patients With Gastric Cancer Recruiting
9 IN-VAC-208 Mucosal melanoma 2 Pembrolizumab NCT05436990 A Phase II Multicenter Study to Assess the Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor Terminated
10 IN-VAC-209 Esophageal Adenocarcinoma 2 NA NCT06044311 A Window of Opportunity Trial Evaluating the Oral TGF-beta Receptor I Inhibitor Vactosertib in Patients Undergoing Standard of Care Chemoradiotherapy for Locally Advanced Esophageal Adenocarcinoma Recruiting

  • [미국, 한국]백토서팁 단독요법

    암종골육종

    임상정보임상 1/2상

    진행현황진행중

    스폰서매드팩토

  • [미국]백토서팁 단독요법

    암종골수증식종양

    임상정보임상 2상

    진행현황종료

    스폰서Weill Medical College of Cornell University

  • [한국]백토서팁 단독요법

    암종진행형 고형암

    임상정보임상 1상

    임진행현황종료

    스폰서매드팩토

  • [미국]백토서팁 단독요법

    암종진행형 고형암

    임상정보임상 1/2상

    임진행현황종료

    스폰서매드팩토

  • [미국]백토서팁 단독요법

    암종골수형성이상증후군

    임상정보임상 1상

    임진행현황종료

    스폰서매드팩토

  • [미국, 한국]키트루다(펨브롤리주맙) 병용

    암종대장암

    임상정보임상 2B/3상

    임진행현황진행중

    스폰서매드팩토

  • [한국]키트루다(펨브롤리주맙) 병용

    암종대장암, 위암

    임상정보임상 1B/2A상

    임진행현황종료

    스폰서매드팩토

  • [미국]키트루다(펨브롤리주맙) 병용

    암종대장암

    임상정보임상 2상

    임진행현황진행중

    스폰서University of California (Chloe Atreya)

  • [한국]키트루다(펨브롤리주맙) 병용

    암종비소세포폐암 1L

    임상정보임상 2상

    임진행현황종료

    스폰서매드팩토

  • [한국]키트루다(펨브롤리주맙) 병용

    암종흑색종

    임상정보임상 2상

    임진행현황종료

    스폰서연세대학교

  • [한국]임핀지(더발루맙) 병용

    암종비소세포폐암 2L

    임상정보임상 1B/2A상

    임진행현황종료(예정)

    스폰서매드팩토

  • [한국]임핀지(더발루맙) 병용

    암종위암

    임상정보임상 2상

    임진행현황진행중

    스폰서국립암센터

  • [한국]탁솔(파클리탁셀) 병용

    암종위암

    임상정보임상 1B/2A상

    임진행현황종료

    스폰서매드팩토

  • [한국]탁솔(파클리탁셀) + 사이람자(라무시루맙) 병용

    암종위암

    임상정보임상 2A상

    임진행현황진행중

    스폰서삼성서울병원

  • [한국]폴폭스(FOLFOX) 병용

    암종췌장암

    임상정보임상 1B상

    임진행현황종료(예정)

    스폰서삼성서울병원

  • [한국]오니바이드(nal-IRI/FL) 병용

    암종췌장암

    임상정보임상 1B상

    임진행현황진행중

    스폰서삼성서울병원

  • [한국]글리벡(이매티닙) 병용

    암종데스모이드종양

    임상정보임상 1B/2A상

    임진행현황종료

    스폰서연세대학교

  • [미국]포말리스트(포말리도마이드) 병용

    암종다발성 골수종

    임상정보임상 1B상

    임진행현황종료

    스폰서Case Comprehensive Cancer Center

  • [미국]화학방사선치료 표준 요법 병용

    암종식도암

    임상정보임상 2상

    임진행현황진행중

    스폰서Case Comprehensive Cancer Center

  • [미국]NK세포치료재 및 인터루킨(IL-2) 병용

    암종대장암, 혈액암

    임상정보임상 1B상

    임진행현황진행중

    스폰서Case Comprehensive Cancer Center


    ‘Clinicaltrial.gov’ Status – SIT for Vactosertib

  • MP-001 (MP-VAC-101)

    IndicationSolid cancer

    Phase1

    CombinationNA

    NCT No.NCT02160106

    Study titleFirst-in-Human Dose-Escalation Study of TEW-7197 Monotherapy in Subjects with Advanced-Stage Solid Tumors

    Actual StatusCompleted

  • MP-GC-01 (MP-VAC-102)

    IndicationGC

    Phase1b/2a

    CombinationPaclitaxel

    NCT No.NCT03698825

    Study titleAn Open-label, Multi center Phase ib/2a study of TEW-7197 (Vactosertib) plus Weekly Paclitaxel as Second-line Treatment for Metastatic Gastric Adenocarcinoma

    Actual StatusCompleted

  • MP-VAC-105

    IndicationFood effect

    Phase1

    CombinationNA

    NCT No.NCT03704675

    Study titleA randomized, open, cross-over design clinical trial to investigate the safety, tolerability, and pharmacokinetics of TEW-7197 after a single oral administration of TEW-7197 200mg under fed or fasting conditions in healthy male subjects

    Actual StatusCompleted

  • MP-MDS-01

    IndicationMDS

    Phase1/2

    CombinationNA

    NCT No.NCT03074006

    Study titlePhase1/2 Study of TEW-7197 Monotherapy in Patients with Low or Intermediate Myelodysplastic Syndromes (MDS)

    Actual StatusCompleted

  • MP-VAC-202

    IndicationUrothelial

    Phase2

    CombinationDurvalumab

    NCT No.NCT04064190

    Study titleA Phase 2 Study of TGF-b inhibitions (Vactosertin) with Anti-PD-L1 (Durvalumab) in Patients with Advanced or Recurrent Urothelial Carcinoma Failing to Achieve Response with Checkpoint Inhibition

    Actual StatusWithdrawn

  • MP-VAC-203

    IndicationNSCLC

    Phase1b/2a

    CombinationDurvalumab

    NCT No.NCT03732274

    Study titlePhase 1b/2a, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Durvalumab in Patients With Advanced Non Small Cell Lung Cancer Who Progressed Following Platinum-based Chemotherapy

    Actual StatusActive, not recruiting

  • MP-VAC-204

    IndicationmCRC

    Phase1b/2a

    CombinationPembrolizumab

    NCT No.NCT03724851

    Study titleA Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of Vactosertib in Combination With Pembrolizumab as a First-line Treatment for Subjects With PD-L1 Positive Advanced Non-Small Cell Lung Cancer

    Actual StatusActive, not recruiting

  • MP-VAC-205

    IndicationNSCLC

    Phase2

    CombinationPembrolizumab

    NCT No.NCT04515979

    Study titleA Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of Vactosertib in Combination With Pembrolizumab as a First-line Treatment for Subjects With PD-L1 Positive Advanced Non-Small Cell Lung Cancer

    Actual StatusTerminated

  • MP-VAC-206

    IndicationDesmoid

    Phase2

    CombinationImatinib

    NCT No.NCT06219733

    Study titleA Phase II, Open-Label, Randomized, Controlled Study to Evaluate Efficacy and Safety of Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor (Aggressive Fibromatosis) Compared With Imatinib Monotherapy

    Actual StatusWithdrawn

  • MP-VAC-209

    IndicationOsteosarcoma

    Phase1b/2a

    CombinationNA

    NCT No.NCT05588648

    Study titleA Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib as a Single Agent in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

    Actual StatusRecruiting


    ‘Clinicaltrial.gov’ Status – IIT for Vactosertib

  • IN-VAC-101

    IndicationMultiple Myeloma

    Phase1

    CombinationPomalidomide

    NCT No.NCT03143985

    Study titleA Phase 1b Trial of Vactosertib in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM)

    Actual StatusCompleted

  • IN-VAC-103

    IndicationPDAC

    Phase1

    CombinationNal-IRI/​FL

    NCT No.NCT04258072

    Study titlePhase 1b Study of Vactosertib (TEW-7197) in Combination With Nal-IRI／FL in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine／Nab-Paclitaxel

    Actual StatusRecruiting

  • IN-VAC-104

    IndicationCRC & AML

    Phase1

    CombinationNK Cell + IL-2

    NCT No.NCT05400122

    Study titleA Phase Ib Study to Evaluate Safety and Persistence of ex Vivo Expanded Universal Donor NK Cells in Combination With IL-2 and TGFbeta Receptor I Inhibitor Vactosertib in Patients With Locally Advanced/Metastatic Colorectal Cancer and Relapsed/Refractory Hematologic Malignancies

    Actual StatusRecruiting

  • IN-VAC-201

    IndicationDesmoid

    Phase1/2

    CombinationImatinib

    NCT No.NCT03802084

    Study titleA Phase 1b/2a, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Imatinib in Patients With Advanced Desmoid Tumor (Aggressive Fibromatosis)

    Actual StatusCompleted

  • IN-VAC-202

    IndicationMPNs

    Phase2

    CombinationNA

    NCT No.NCT04103645

    Study titleA 2-tiered, Phase 2, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) in the Treatment of Anemic Patients With Philadelphia Chromosome-negative MPNs (Ph-neg MPNs)

    Actual StatusTerminated

  • IN-VAC-203

    IndicationGastric

    Phase2

    CombinationPaclitaxel+Ramucirumab

    NCT No.NCT04656002

    Study titleAs a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase 2a Clinical Trial to Biomarkers

    Actual StatusRecruiting

  • IN-VAC-205

    IndicationCRC,resectable Hepatic Metastases

    Phase2

    CombinationNA

    NCT No.NCT03844750

    Study titleA Phase II Study of Preoperative Immunotherapy in Patients With Colorectal Cancer and Resectable Hepatic Metastases

    Actual StatusRecruiting

  • IN-VAC-207

    IndicationGastric

    Phase2

    CombinationDurvalumab

    NCT No.NCT04893252

    Study titleVactosertib in Combination With Durvalumab (MEDI4736) in Patients With Gastric Cancer

    Actual StatusRecruiting

  • IN-VAC-208

    IndicationMucosal melanoma

    Phase2

    CombinationPembrolizumab

    NCT No.NCT05436990

    Study titleA Phase II Multicenter Study to Assess the Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor

    Actual StatusTerminated

  • IN-VAC-209

    IndicationEsophageal Adenocarcinoma

    Phase2

    CombinationNA

    NCT No.NCT06044311

    Study titleA Window of Opportunity Trial Evaluating the Oral TGF-beta Receptor I Inhibitor Vactosertib in Patients Undergoing Standard of Care Chemoradiotherapy for Locally Advanced Esophageal Adenocarcinoma

    Actual StatusRecruiting

Presentations & Publications

Total 0

  • Mar, 2025

    Tm4sf19 inhibition ameliorates inflammation and bone destruction in collagen-induced arthritis by suppressing TLR4-mediated inflammatory signaling and abnormal osteoclast activation

    Bone Research
    Download

  • Nov, 2024

    MIMERET, a Novel Mitochondrial-Targeted Drug, Improves Hepatic Steatosis by Stimulating Mitochondrial Fatty Acid Beta-Oxidation to Prevent Lipid Accumulation

    AASLD 2024
    Download

  • Nov, 2024

    Vactosertib, a TGF-β signaling inhibitor, in combination with Durvalumab increased mOS in ≥2L treatment of patients with PD-L1-positive advanced NSCLC

    SITC 2024
    Download

  • Aug, 2024

    The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial

    Nature Communications
    Download

  • Jul, 2024

    Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

    Cancer Communications
    Download

  • Apr, 2024

    Novel combination therapy for treating proteasome inhibitor-resistant multiple myeloma

    AACR 2024
    Download

  • Apr, 2024

    Oral TGF-beta receptor1 inhibitor, Vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

    AACR 2024
    Download

  • Feb, 2024

    Clinical activity of transforming growth factor-β inhibitor vactosertib in combination 3 with imatinib in desmoid tumors: a multicenter phase Ib/II study

    Clinical Cancer Research
    Download

  • Nov, 2023

    A Competitive Inhibitor of MOART Showed Potent Therapeutic Effects in a Mouse Model of Collagen-induced Arthritis

    미국류마티스학회 2023(ACR 2023)
    Download

  • Oct, 2023

    Efficacy and Safety of Vactosertib and Pembrolizumab Combination in Patients with Previously Treated Microsatellite Stable Metastatic Colorectal Cancer

    유럽종양학회(ESMO)
    Download

  • Apr, 2023

    Vactosertib combined treatment with T1-44, a PRMT5 activity inhibitor, improves the survival and inhibits tumor invasion of murine pancreatic cancer model

    American Association for Cancer Research 2023(AACR 2023)
    Download

  • Feb, 2023

    Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors

    Cell Death and Disease (2023)
    Download

  • Jan, 2023

    Discovery of TRD-93 as a novel DRAK2 inhibitor

    BULLETIN OF THE KOREAN CHEMICAL SOCIETY
    Download

  • Dec, 2022

    MAST4 controls cell cycle in spermatogonial stem cells

    Cell proliferation(IF : 8.755)
    Download

  • Dec, 2022

    Therapeutic Implications of TGF-β Pathway in Desmoid Tumor Based on Comprehensive Molecular Profiling and Clinicopathological Properties

    Cancers
    Download

  • Oct, 2022

    ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cance

    Nature communication
    Download

  • Sep, 2022

    Phase 1b Study of Vactosertib in Combination with FOLFOX in Patients with Metastatic Pancreatic Ductal Adenocarcinoma who have Failed First-Line Gemcitabine/nab-Paclitaxel

    미국암연구학회 췌장암 특별 컨퍼런스(AACR Special Conference on Pancreatic Cancer)2022
    Download

  • Jan, 2022

    Phase 1b Study of Vactosertib in Combination with nal-IRI plus 5FU/LV in Patients with Metastatic Pancreatic Ductal Adenocarcinoma who Failed First-Line Gemcitabine/nab-Paclitaxel

    미국임상종양학회 위장관종양심포지엄(ASCO GI) 2022
    Download

  • Nov, 2021

    Tumor Microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the survival of MSS mCRC patients treated vactosertib in combination with pembrolizumab

    미국 면역항암학회(SITC) 2021
    Download

  • Nov, 2021

    Spatial analysis of tumor-infiltrating lymphocytes correlates with the response of metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab

    미국 면역항암학회(SITC) 2021
    Download

  • Jun, 2021

    Efficacy and Safety of Vactosertib and Pembrolizumab Combination in Patients with Previously Treated Microsatellite Stable Metastatic Colorectal Cancer

    미국임상종양학회(ASCO) 2021
    Download

  • Jun, 2021

    Phase 1b trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach by Targeting TGF-β Signaling Pathway

    미국임상종양학회(ASCO) 2021
    Download

  • Apr, 2021

    BAG2 Promotes Tumorigenesis and Metastasis by Regulating the Cathepsin B Cleavage in Triple Negative Breast Cancer Cells

    미국 암학회(AACR) 2021
    Download

  • Apr, 2021

    DRAK1 suppresses inflammation induced cervical cancer progression by targeting TRAF6 protein

    미국 암학회 (AACR) 2021
    Download

  • Apr, 2021

    Beneficial effect of vactosertib combined with nal IRI5 FULV in pancreatic cancer treatment

    미국 암학회 (AACR) 2021
    Download

  • Apr, 2021

    Genomic and transcriptomic analyses of desmoid tumor reveals enrichment of transforming growth factor beta responsive signature

    미국 암학회 (AACR) 2021
    Download

  • Nov, 2020

    Vactosertib and Durvalumab as Second or Later Line Treatment for PD-L1 Positive Non-small Cell Lung Cancer: Interim Result

    미국 면역항암학회 (SITC) 2020
    Download

  • Sep, 2020

    Safety and Efficacy of Vactosertib, a TGFBR1 Kinase Inhibitor, in Combination with Paclitaxel in Patients with Metastatic Gastric Adenocarcinoma

    유럽종양학회 연례회의 (ESMO) Congress 2020
    Download

  • May, 2020

    A Phase 1 study of TGF-β inhibitor, Vactosertib, in combination with Imatinib in patients with advanced desmoid tumor (aggressive fibromatosis)

    미국임상종양학회 (ASCO) 2020
    Download

  • Nov, 2019

    Safety and Preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase inhibitor, in combination with Durvalumab in advanced Non-small cell lung cancer patients with low PD-L1 expression

    미국면역암학회 (SITC) 2019
    Download

  • Nov, 2019

    Safety and preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase inhibitor, in combination with Pembrolizumab in patients with metastatic colorectal or gastric cancer

    미국면역암학회 (SITC) 2019
    Download

  • Nov, 2019

    TGF-β as a promising therapeutic target for treating Osteosarcoma

    Innovation in AYA cancer
    Download

  • Jun, 2018

    TGF-β Responsive signature is associated with anti-tumor effect of Vactosertib, a potent oral TGF-β receptor type1(TGFBRI) inhibitor in patients with advanced solid tumors

    미국임상종양학회 (ASCO) 2018
    Download